Laigo Bio Secures €17 Million in Seed Funding
Laigo Bio, a biotechnology company based in Utrecht, The Netherlands, has successfully raised €17 million in a seed funding round. The funding, completed on March 23, 2026, was co-led by Biovance Capital and Kurma Partners, with participation from several other investors including Curie Capital, Argobio Studio, Angelini Ventures, Eurazeo, Oncode Bridge Fund, ROM Utrecht Region, and Cancer Research Horizons.
Company Overview
Laigo Bio specializes in developing innovative therapies using its proprietary SureTACs™ platform. This technology focuses on precision membrane protein degradation, creating bispecific antibodies that target and degrade disease-causing proteins with high specificity. The company aims to leverage this platform to develop first-in-class therapies for oncology and auto-immune disorders.
Key Leadership
The company was founded by Madelon Maurice, who serves as the Scientific Lead, and Matthew Baker, who holds the position of Chief Executive Officer. Dr. Baker commented on the funding achievement, stating: "This investment allows us to accelerate our oncology and auto-immunity programs, bringing us closer to clinical trials."
Use of Funds
The newly acquired funds will be directed towards advancing Laigo Bio's SureTACs™ technology. Specifically, the company plans to push its oncology programs further towards clinical trials. Additionally, Laigo Bio will focus on developing three candidate programs targeting specific autoimmune and immunology indications, as well as addressing graft rejection issues.
Lead Investors
Biovance Capital and Kurma Partners led the seed funding round, contributing significantly to the total amount raised. The involvement of these investors underscores their confidence in Laigo Bio's innovative approach and its potential impact on the biotech industry.
Laigo Bio's successful seed funding round marks a significant step forward in its mission to develop groundbreaking therapies for challenging health conditions. The company is now well-positioned to enhance its research and development efforts, bringing novel treatments closer to reality.